3 New Studies Show Hemispherx Biopharma's Ampligen(R) And Alferon(R) LDO May Provide Defense Against Avian Flu

Hemispherx Biopharma, Inc. (AMEX: HEB): Tests Indicate Potential of Ampligen(R) As Vaccine Adjuvant, Boosts Existing Drugs Tamiflu(R), Relenza(R) Up To 100 Times; Alferon(R) LDO Found to Stimulate Production of Interferon, Offering Natural Defense Against Virus

Consortium of Researchers to Present Findings at Today's ASM Biodefense Research Meeting in Washington, D.C.

Hemispherx Biopharma, Inc. (AMEX: HEB), a leader in the clinical development and production of new drug entities for the treatment of viral and immune-based chronic disorders, today unveiled the results of laboratory testing that shows its two investigational immunotherapeutics, Ampligen(R) and Alferon(R), are potentially useful against the H5N1, or avian flu, virus. The pre-clinical research indicates that Ampligen(R), a specifically configured double-stranded RNA, can provide cross-protection against avian flu viral mutations as well as boost the effectiveness of Tamiflu and Relenza, the only two drugs formally recognized for combating bird flu, up to 100 times. Other lab tests, in healthy human volunteers, indicate that Alferon(R) LDO (Low-Dose Oral), a new delivery form of an anti-viral with prior regulatory approval for a category of sexually transmitted diseases, can stimulate genes that induce the production of interferon and other immune compounds, key building blocks in the body's defense system. Hemispherx Biopharma and collaborating government scientists are presenting detailed findings at today's American Society for Microbiology Biodefense Research Meeting in Washington, DC.

Read Full Article Here (Interesting)